Autolus Therapeutics to participate in Investor Conferences through January
January 04 2021 - 7:00AM
Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage
biopharmaceutical company developing next-generation programmed T
cell therapies, today announced that management will participate in
investor conferences through January 2021.
- 11 January 2021 –
The company will present at the H.C. Wainwright BioConnect
2021 Conference which will be available on demand as of
6:00 am ET, 11 am GMT on Monday, January 11, 2021. The webcast will
be available on the investor relations section of the Company’s
website at Autolus.
- 13 January 2021 –
The company will present at the 39th Annual J.P. Morgan
Healthcare Conference on Wednesday, January 13, 2021 at
9:10 am ET, 2.10 pm GMT. The Company will host virtual one-on-one
meetings at the J.P. Morgan event and a live audio webcast will be
available on the investor relations section of the Company’s
website at Autolus.
Archived replays will be available for a period
of 30 days after the conferences.
About Autolus Therapeutics
plc
Autolus is a clinical-stage biopharmaceutical
company developing next-generation, programmed T cell therapies for
the treatment of cancer. Using a broad suite of proprietary and
modular T cell programming technologies, the company is engineering
precisely targeted, controlled and highly active T cell therapies
that are designed to better recognize cancer cells, break down
their defense mechanisms and eliminate these cells. Autolus has a
pipeline of product candidates in development for the treatment of
hematological malignancies and solid tumors. For more information
please visit www.autolus.com.
Contact:
Lucinda Crabtree, PhDVice President, Investor
Relations and Corporate Communications+44 (0) 7587 372
619 l.crabtree@autolus.com
Julia Wilson+44 (0) 7818
430877j.wilson@autolus.com
Susan A. NoonanS.A. Noonan
Communications+1-212-966-3650susan@sanoonan.com
Autolus Therapeutics (NASDAQ:AUTL)
Historical Stock Chart
From Aug 2024 to Sep 2024
Autolus Therapeutics (NASDAQ:AUTL)
Historical Stock Chart
From Sep 2023 to Sep 2024